GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Cyclically Adjusted PB Ratio

Enlivex Therapeutics (Enlivex Therapeutics) Cyclically Adjusted PB Ratio : 0.06 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Enlivex Therapeutics's current share price is $1.6005. Enlivex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $24.86. Enlivex Therapeutics's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Enlivex Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ENLV' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.17
Current: 0.07

During the past years, Enlivex Therapeutics's highest Cyclically Adjusted PB Ratio was 0.17. The lowest was 0.00. And the median was 0.00.

ENLV's Cyclically Adjusted PB Ratio is ranked better than
91.61% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs ENLV: 0.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enlivex Therapeutics's adjusted book value per share data for the three months ended in Sep. 2023 was $2.085. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $24.86 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enlivex Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Enlivex Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Cyclically Adjusted PB Ratio Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.16 -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.14 0.10 0.06 -

Competitive Comparison of Enlivex Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Enlivex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Cyclically Adjusted PB Ratio falls into.



Enlivex Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enlivex Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.6005/24.86
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Enlivex Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=2.085/129.8595*129.8595
=2.085

Current CPI (Sep. 2023) = 129.8595.

Enlivex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.643 98.326 0.849
201403 0.000 99.695 0.000
201406 10.585 100.560 13.669
201409 93.867 100.428 121.376
201412 86.221 99.070 113.018
201503 78.972 99.621 102.943
201506 70.640 100.684 91.110
201509 62.143 100.392 80.384
201512 50.405 99.792 65.592
201603 56.721 100.470 73.313
201606 37.793 101.688 48.263
201609 27.748 101.861 35.375
201612 21.228 101.863 27.062
201703 15.296 102.862 19.311
201706 11.303 103.349 14.202
201709 8.966 104.136 11.181
201712 7.568 104.011 9.449
201803 0.000 105.290 0.000
201806 3.715 106.317 4.538
201809 0.000 106.507 0.000
201812 21.833 105.998 26.748
201903 1.363 107.251 1.650
201906 1.519 108.070 1.825
201909 1.334 108.329 1.599
201912 1.092 108.420 1.308
202003 2.387 108.902 2.846
202006 2.242 108.767 2.677
202009 2.117 109.815 2.503
202012 2.433 109.897 2.875
202103 4.950 111.754 5.752
202106 4.928 114.631 5.583
202109 4.805 115.734 5.391
202112 4.639 117.630 5.121
202203 4.226 121.301 4.524
202206 3.726 125.017 3.870
202209 3.437 125.227 3.564
202212 3.086 125.222 3.200
202303 2.724 127.348 2.778
202306 2.385 128.729 2.406
202309 2.085 129.860 2.085

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enlivex Therapeutics  (NAS:ENLV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enlivex Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus

Enlivex Appoints Andrew Singer to its Board of Directors

By sperokesalga sperokesalga 04-17-2023

Enlivex Announces Upcoming May Conference Presentations

By GuruFocusNews GuruFocusNews 07-09-2022